Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2020 Earnings Conference Call - Final Transcript
May 04, 2020 • 08:30 am ET
Greetings, and welcome to the Marinus Pharmaceuticals First Quarter 2020 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Sasha Damouni Ellis, Vice President, Investor Relations. Thank you. You may begin, Ms. Ellis.
Sasha Damouni Ellis
Thank you. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; and Edward Smith, Chief Financial Officer.
Before we begin, I would like to remind everyone that some of the statements made today could be termed as forward-looking under the securities law. These forward-looking statements, of course, are subject to certain risk and uncertainties that are associated with our business and covered in part in the Company's Form 10-K and 10-Q as filed with the Securities and Exchange Commission.
I will now turn the call over to Scott.
Thank you, Sasha. Good morning, everyone, and welcome to our first quarter 2020 business and financial update. As Sasha mentioned, today on the call, I have with me Dr. Joe Hulihan, Chief Medical Officer, who will provide updates on our clinical progress; and Ed Smith, our Chief Financial Officer, who will review our financial statements and the Company's cash position. We will be available for questions at the end of the call.
Starting off today's call, I would like to acknowledge that this marks our first earnings and business update conference call. This is an important milestone that reflects the significant progress we have made and the evolution of Marinus to a company that is nearing pivotal trial data with the potential for both an NDA filing and a commercial launch. We have continued our momentum over the past few quarters with several milestones, including promising clinical data from our program in status epilepticus and important financing prior to year-end, the implementation of a broader strategic clinical plan designed to unlock the potential of ganaxolone across a range of rare seizure disorders and an encouraging interaction with the FDA that we will describe in more detail for you shortly. 2020 has already turned out to be an exciting time at Marinus, and we look forward to having our quarterly calls as an opportunity to keep our shareholders up to date and well informed.
I'd like to take a moment to acknowledge the ongoing COVID-19 pandemic. At Marinus, we have been fortunate that, as of today, we have avoided the major impacts and delays that have been so challenging for many of our colleagues across the life sciences. We are encouraged that our upcoming clinical milestones, which include top line data from our Phase III pivotal trial in CDKL5 deficiency disorder or CDD, and the initiation of our Phase II trial in tuberous sclerosis complex or TSC remain on track. I am grateful for the continued commitment and dedication of our team and our investigators. They have enabled us to successfully navigate this unprecedented and challenging time. This has been a difficult period for all of us, and our entire organization